This is well written, but there have been many more flaws pointed out in the ICER's logic. I recently co-authored an article pointing out a lot of these issues (https://www.journalofpsychedelicpsychiatry.org/current-issue). I worry blocking this treatment is going to lead to more harm than any possible risk mitigation from delaying the approval. The goal posts will just keep getting pushed further and further back while patients continue to struggle, only having a few "FDA approved" options to choose from.
This is well written, but there have been many more flaws pointed out in the ICER's logic. I recently co-authored an article pointing out a lot of these issues (https://www.journalofpsychedelicpsychiatry.org/current-issue). I worry blocking this treatment is going to lead to more harm than any possible risk mitigation from delaying the approval. The goal posts will just keep getting pushed further and further back while patients continue to struggle, only having a few "FDA approved" options to choose from.
could you clarify what are those novel psychoplastogens for PTSD without psychoactive effects?
This is a question for guest author @Alison mcinnnes....